skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

12281

Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections



Review

(5049) Total Article Views


Authors: Emily Zoller, Connie Valente, Kyle Baker, et al

Published Date November 2010 Volume 2010:4 Pages 299 - 311
DOI: http://dx.doi.org/10.2147/DDDT.S7773

Emily Zoller, Connie Valente, Kyle Baker, Michael E Klepser
Ferris State University College of Pharmacy, Kalamazoo, Michigan, USA

Abstract: Posaconazole is an extended-spectrum azole antifungal that exhibits activity against a broad range of fungal pathogens, including yeasts and moulds. Clinical data have demonstrated the clinical utility of posaconazole against many therapy-refractory pathogens, including Aspergillus spp, Fusarium spp, and Zygomycetes. These data have provided clinicians with hope in these difficult situations. Some of the limitations that have emerged with the use of posaconazole are the lack of an intravenous formulation and erratic drug absorption. This fact is further complicated by the existence of saturable posaconazole absorption. Despite these drawbacks, posaconazole appears poised to become a prominent therapeutic modality for the prophylaxis and management of various fungal infections among high-risk patients.

Keywords: posaconazole, pharmacokinetics, fungal infections


Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter


Readers of this article also read:
  • Testimonials

    "I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University.